Construction of a novel multi-gene assay (42-gene classifier) for prediction of late recurrence in ER-positive breast cancer patients

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

(2017) Hongchao Pan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor–Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14

(2016) Norman Wolmark et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy

(2016) Richard Buus et al.   JNCI-Journal of the National Cancer Institute

Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer

(2016) Pattaraporn Wangchinda et al.   World Journal of Surgical Oncology

Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer

(2016) Akiko Ogiya et al.   Breast Cancer

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy

(2016) Richard Buus et al.   JNCI-Journal of the National Cancer Institute

Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer

(2015) Arran K. Turnbull et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer

(2015) Hiroko Yamashita et al.   Breast Cancer

The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer

(2014) Martin Filipits et al.   CLINICAL CANCER RESEARCH

Acid ceramidase is associated with an improved prognosis in both DCIS and invasive breast cancer

(2014) Nicole Sänger et al.   Molecular Oncology

Construction of novel immune-related signature for prediction of pathological complete response to neoadjuvant chemotherapy in human breast cancer

(2013) Y. Sota et al.   ANNALS OF ONCOLOGY

Comparison of efficacy of 95-gene and 21-gene classifier (Oncotype DX) for prediction of recurrence in ER-positive and node-negative breast cancer patients

(2013) Yasuto Naoi et al.   BREAST CANCER RESEARCH AND TREATMENT

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

(2013) P Dubsky et al.   BRITISH JOURNAL OF CANCER

Breast Cancer Index Identifies Early-Stage Estrogen Receptor-Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence

(2013) Y. Zhang et al.   CLINICAL CANCER RESEARCH

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer

(2013) Ivana Sestak et al.   JNCI-Journal of the National Cancer Institute

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population

(2013) Dennis C Sgroi et al.   LANCET ONCOLOGY

The Difference in Prognostic Factors between Early Recurrence and Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Nodal Stage Differently Impacts Early and Late Recurrence

(2013) Sung Gwe Ahn et al.   PLoS One

Protein Tyrosine Phosphatase 4A2 Expression Predicts Overall and Disease-Free Survival of Human Breast Cancer and Is Associated with Estrogen and Progestin Receptor Status

(2013) Sarah A. Andres et al.   Hormones & Cancer

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

(2012) Christina Davies et al.   LANCET

RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data

(2011) Balázs Győrffy et al.   BREAST CANCER RESEARCH AND TREATMENT

Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients

(2010) Yasuto Naoi et al.   BREAST CANCER RESEARCH AND TREATMENT

Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial

(2008) Eleftherios P. Mamounas et al.   JOURNAL OF CLINICAL ONCOLOGY